Tarlatamab treatment

Phase 2Small molecule

Tarlatamab treatment is one of 50 small molecule programs targeting Neuroendocrine Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmActive, not recruiting

Neuroendocrine NeoplasmPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Neuroendocrine Neoplasm

#DrugCompanyPhaseTrials

Lynparza

Kisqali

Arava

Lenvima

Talzenna

Nolvadex

Afinitor

Lithobid

SSolvay Pharmaceuticals

Farydak

Signifor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Neuroendocrine Neoplasm

NCT06788938

Clinical

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06788938·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tarlatamab treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tarlatamab treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tarlatamab treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Tarlatamab treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

References

Drug Info

Quick Facts

Related News